secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000950170-24-067660
Event type: other
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors
--------------------------------------------------------------------------------

- Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).
- Sandesh Mahatme and Christian Rommel elected as new Board members; all incumbent directors re-elected.
- Articles of Association amended: capital band increased to CHF 3,100,452; equity/pension practices updated.
- Binding vote on Board equity grants passed 32.2M for vs 10.7M against; 2023 compensation report endorsed non-binding.
- Proposal to transact other business was rejected (21.9M against, 20.3M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024067660/0000950170-24-067660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024067660/crsp-20240530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer